Model-guided medicine for early diagnosis of transthyretin-associated cardiac amyloidosis using multimodal data integration and standardized interoperable models (the CRONOS-ATTR study) - Summary - MDSpire

Model-guided medicine for early diagnosis of transthyretin-associated cardiac amyloidosis using multimodal data integration and standardized interoperable models (the CRONOS-ATTR study)

  • By

  • Raúl Ramos-Polo

  • Sergi Yun

  • Lorena Herrador

  • Fernando de Frutos

  • Sílvia Jovells-Vaqué

  • Andreea Eunice Cosa

  • Alejandro Espinosa

  • Adrian Ricarte Marin

  • Hugo Herrero Antón de Vez

  • Oriol Guardia

  • Carlos Casasnovas

  • Cristina Enjuanes

  • Jaime Reventós Puigjaner

  • Jose González-Costello

  • Josep Comín-Colet

  • June 24, 2026

  • 0 min

Share

Objective:

To explore the feasibility and efficacy of integrating AI algorithms from different vendors within a model-guided medicine framework for early detection of transthyretin cardiac amyloidosis (ATTR-CM).

Approach:
  • Study Design: The CRONOS-ATTR study was a single-center, prospective, observational study involving 124 heart failure patients with suspected cardiac amyloidosis.
  • Patient Recruitment: Patients included 30 with hereditary ATTR-CM, 65 with wild-type ATTR-CM, and 29 without ATTR-CM, recruited between December 2022 and December 2023.
  • Diagnostic Confirmation: Diagnosis of ATTR-CM was confirmed via 99mTc-DPD scintigraphy and hematologic testing, with genetic testing performed for classification.
  • Data Integration: The study aimed to integrate clinical data, ECG, and echocardiographic features into a patient-specific model using AI algorithms.
Key Findings:
  • ATTR-CM is often underdiagnosed due to nonspecific symptoms and late-stage clinical markers.
  • AI-enhanced approaches can potentially facilitate early detection of ATTR-CM.
  • The CRONOS-ATTR framework aims to provide interpretable insights to improve diagnostic accuracy.
Interpretation:

Limitations:
  • The study was conducted at a single center, which may limit generalizability.
  • Exclusion of patients with AL or secondary amyloidosis may affect the applicability of findings.
Conclusion:

Original Source(s)

Model-guided medicine for early diagnosis of transthyretin-associated cardiac amyloidosis using multimodal data integration and standardized interoperable models (the CRONOS-ATTR study)

  • by Raúl Ramos-Polo, Sergi Yun, Lorena Herrador, Fernando de Frutos, Sílvia Jovells-Vaqué, Andreea Eunice Cosa, Alejandro Espinosa, Adrian Ricarte Marin, Hugo Herrero Antón de Vez, Oriol Guardia, Carlos Casasnovas, Cristina Enjuanes, Jaime Reventós Puigjaner, Jose González-Costello, Josep Comín-Colet

  • June 24, 2026

Related Content

Patterns and risk factors of hyperkalemia recurrence among heart failure patients

Early aortic valve intervention versus clinical surveillance in patients with asymptomatic severe aortic stenosis: a systematic review and meta-analysis

Acute aortic regurgitation due to aortic valve leaflet injury during percutaneous coronary intervention: a case report